News
Media
Conferences
Events
Publication
CME/CE
Resources
Editorial Advisory Board
Partners
Subscribe

Opinion|Videos|August 1, 2024

Long-Term Efficacy and Insights from POETYK PSO-1 Studies: Implications for Psoriasis Treatment

Author(s)Alexa Hetzel, MS, PA-C, Andrew Mastro, MS, PA-C , TJ Chao, MPAS, PA-C

Physicians examine the enduring effectiveness and key findings from the POETYK PSO-1 clinical trials, evaluating their impact on the evolving landscape of psoriasis treatment options.

Episodes in this series

4 KOLs are featured on this panel.

EP. 1 Navigating Plaque Psoriasis: Insights into the Psychosocial Impact and Evolving Treatment Landscape

4 KOLs are featured on this panel.

EP. 2 Plaque Psoriasis Case Study: Patient Presentation, Treatment Selection, and Shared Decision-Making for Improved Outcomes

4 KOLs are featured on this panel.

EP. 3 Empowering Patients with Plaque Psoriasis: Navigating Treatment Challenges Informed Patient Conversations and Decision Trees

4 KOLs are featured on this panel.

EP. 4 A Conversation on Combination Therapy, Safety Profiles, and Targeted IL-17 Systemic Treatments

4 KOLs are featured on this panel.

EP. 5 Clinical Insights: Managing Psoriasis Treatment Dynamics and Strategic Therapy Switching Considerations

4 KOLs are featured on this panel.

EP. 6 Head-to-Head Clinical Trials: Comparing Psoriasis Treatment Response Rates

4 KOLs are featured on this panel.

EP. 7 TYK2 Inhibition and Deucravacitinib: Mechanism of Action, Safety Considerations, and Patient-Provider Conversations

4 KOLs are featured on this panel.

EP. 8 Comparative Analysis: Deucravacitinib and Adalimumab in Psoriasis Treatment

4 KOLs are featured on this panel.

EP. 9 Understanding IL-17 Therapies: Treatment Considerations, Rapid Response, and Impact on Plaque Psoriasis Location

4 KOLs are featured on this panel.

EP. 10 Expert Insights into Managing Inadequate Response to Systemic Therapies: Strategies and Solutions

4 KOLs are featured on this panel.

EP. 11 Long-Term Efficacy and Insights from POETYK PSO-1 Studies: Implications for Psoriasis Treatment

4 KOLs are featured on this panel.

EP. 12 Achieving Durable Responses: Physician's Guide to Interpreting Long-Term Efficacy Data

4 KOLs are featured on this panel.

EP. 13 When to Discontinue Treatment: Interpreting Safety Signals and Adverse Event Patterns

4 KOLs are featured on this panel.

EP. 14 Updating Treatment Guidelines: Incorporating Novel Therapies to Address Unmet Needs

EP. 15 Available Psoriasis, Patient Involvement, and Holistic Treatment

EP. 15 Available Psoriasis, Patient Involvement, and Holistic Treatment

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Content

Addressing Delays in Prior Authorization Processes That Negatively Impact Patients

ByJohn Barbieri, MD, MBA, FAAD,Kaitlyn Bader, Assistant Managing Editor

December 12th 2025

JAK Inhibitors Show Comparable Safety to TNF Antagonists

ByMaddi Hebebrand, MC, Associate Editor

December 12th 2025

Meta-analysis Confirms Benefits of Roflumilast 0.3% Cream for PsO

ByMaddi Hebebrand, MC, Associate Editor

December 9th 2025

Nearly Half of Female Psoriasis Patients Report IPV, Study Finds

ByMaddi Hebebrand, MC, Associate Editor

December 5th 2025

Guselkumab Demonstrates Durable Joint-Protective Effects Through 48 Weeks in Active PsA

ByMarie Bosslett, Assistant Editor

November 21st 2025

Latest CME

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Brad P. Glick, DO, MPH, FAAD

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Corey Cutler, MD, MPH, FRCP(C); Amin M. Alousi, MD; Mehdi Hamadani, MD; Anna Sureda, MD, PhD

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Hilary Baldwin; Neal Bhatia, MD

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

In-Person Event

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

June 17-19, 2026

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Trending on Dermatology Times

Transformative Advances This Year and Beyond

FDA Proposes Expansion of US Sunscreen Ingredient Standards with Bemotrizinol

Phase 3b Study Confirms Ligelizumab’s Consistent CSU Control

"PDE4 Inhibitor-Responsive Dermatoses": A Modern Framework for Managing Inflammatory Skin Conditions

Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population

© 2025 MJH Life Sciences^®

All rights reserved.